Back to top
more

TG Therapeutics (TGTX)

(Real Time Quote from BATS)

$17.24 USD

17.24
504,620

+0.12 (0.70%)

Updated May 9, 2024 11:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of 22.22% and 105.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics (TGTX) Surges 22.8%: Is This an Indication of Further Gains?

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know

TG Therapeutics (TGTX) closed at $15.48 in the latest trading session, marking a -1.46% move from the prior day.

TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know

TG Therapeutics (TGTX) closed the most recent trading day at $14.63, moving -1.48% from the previous trading session.

TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, TG Therapeutics (TGTX) closed at $14.70, marking a -1.41% move from the previous day.

TG Therapeutics (TGTX) Stock Moves -0.6%: What You Should Know

In the latest trading session, TG Therapeutics (TGTX) closed at $14.79, marking a -0.6% move from the previous day.

TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Universal Health Services (UHS) Tops Q4 Earnings and Revenue Estimates

Universal Health Services (UHS) delivered earnings and revenue surprises of 2.03% and 1.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should Know

TG Therapeutics (TGTX) closed at $19.34 in the latest trading session, marking a +1.79% move from the prior day.

TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know

TG Therapeutics (TGTX) closed the most recent trading day at $18.43, moving -0.27% from the previous trading session.

TG Therapeutics (TGTX) Stock Moves -0.89%: What You Should Know

In the latest trading session, TG Therapeutics (TGTX) closed at $14.50, marking a -0.89% move from the previous day.

TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should Know

TG Therapeutics (TGTX) closed at $13.20 in the latest trading session, marking a +0.61% move from the prior day.

TG Therapeutics (TGTX) Soars 8.7%: Is Further Upside Left in the Stock?

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

TG Therapeutics (TGTX) Upgraded to Buy: What Does It Mean for the Stock?

TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Company News for Dec 30, 2022

Companies in The News Are: IMGN, TGTX, TSLA, MSFT

TG Therapeutics (TGTX) Gets FDA Nod for Multiple Sclerosis Drug

The FDA approves TG Therapeutics' (TGTX) Briumvi (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis. The company plans to launch the drug in the first quarter of 2023. Stock up.

Can TG Therapeutics (TGTX) Climb 155% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for TG Therapeutics (TGTX) points to a 154.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Indrajit Bandyopadhyay headshot

3 Medical Products Stocks Navigating Industry Challenges (Revised)

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.

Zacks Industry Outlook Highlights QuidelOrtho, Lantheus and TG Therapeutics

QuidelOrtho, Lantheus and TG Therapeutics are part of Zacks Industry Outlook article.

Indrajit Bandyopadhyay headshot

3 Medical Products Stocks Navigating Industry Challenges

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.

TG Therapeutics (TGTX) Upgraded to Buy: Here's Why

TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does TG Therapeutics (TGTX) Have the Potential to Rally 151% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 151.2% in TG Therapeutics (TGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

TG Therapeutics (TGTX) Reports Q3 Loss, Lags Revenue Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of 21.21% and 97.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?